Natixis Advisors LLC Purchases 194,665 Shares of Prestige Consumer Healthcare Inc. (NYSE:PBH)

Natixis Advisors LLC boosted its stake in Prestige Consumer Healthcare Inc. (NYSE:PBH) by 1,335.1% in the 4th quarter, Holdings Channel reports. The firm owned 209,246 shares of the company’s stock after acquiring an additional 194,665 shares during the quarter. Natixis Advisors LLC’s holdings in Prestige Consumer Healthcare were worth $16,340,000 at the end of the most recent reporting period.

Several other large investors have also added to or reduced their stakes in the stock. Swiss National Bank boosted its stake in Prestige Consumer Healthcare by 0.5% in the 4th quarter. Swiss National Bank now owns 97,500 shares of the company’s stock worth $7,614,000 after purchasing an additional 500 shares during the period. Great Lakes Advisors LLC boosted its stake in Prestige Consumer Healthcare by 113.7% in the 4th quarter. Great Lakes Advisors LLC now owns 139,116 shares of the company’s stock worth $10,864,000 after purchasing an additional 74,016 shares during the period. HighTower Advisors LLC boosted its stake in Prestige Consumer Healthcare by 89.5% in the 4th quarter. HighTower Advisors LLC now owns 31,666 shares of the company’s stock worth $2,473,000 after purchasing an additional 14,958 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in Prestige Consumer Healthcare by 7.1% in the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 11,053 shares of the company’s stock worth $863,000 after purchasing an additional 731 shares during the period. Finally, Amundi boosted its stake in Prestige Consumer Healthcare by 187.4% in the 4th quarter. Amundi now owns 25,669 shares of the company’s stock worth $1,909,000 after purchasing an additional 16,737 shares during the period. Institutional investors own 99.95% of the company’s stock.

Analysts Set New Price Targets

Several brokerages have commented on PBH. StockNews.com upgraded Prestige Consumer Healthcare from a “hold” rating to a “buy” rating in a research note on Tuesday. Canaccord Genuity Group raised their price target on Prestige Consumer Healthcare from $93.00 to $100.00 and gave the company a “buy” rating in a report on Friday, February 7th. Raymond James raised Prestige Consumer Healthcare to a “moderate buy” rating in a report on Thursday, December 19th. Oppenheimer raised their price target on Prestige Consumer Healthcare from $87.00 to $93.00 and gave the company an “outperform” rating in a report on Thursday, February 13th. Finally, Sidoti cut Prestige Consumer Healthcare from a “buy” rating to a “neutral” rating and set a $90.00 price target on the stock. in a report on Monday, December 9th. Two equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $92.60.

Prestige Consumer Healthcare Stock Performance

Shares of NYSE PBH opened at $84.01 on Wednesday. The stock has a market cap of $4.16 billion, a price-to-earnings ratio of 19.67, a P/E/G ratio of 2.69 and a beta of 0.46. The company has a current ratio of 3.68, a quick ratio of 2.20 and a debt-to-equity ratio of 0.56. Prestige Consumer Healthcare Inc. has a 1-year low of $62.35 and a 1-year high of $90.04. The stock’s 50-day moving average is $81.87 and its 200 day moving average is $78.45.

Prestige Consumer Healthcare (NYSE:PBH) last announced its quarterly earnings data on Thursday, February 6th. The company reported $1.22 earnings per share for the quarter, beating analysts’ consensus estimates of $1.18 by $0.04. Prestige Consumer Healthcare had a return on equity of 12.36% and a net margin of 19.13%. On average, sell-side analysts anticipate that Prestige Consumer Healthcare Inc. will post 4.5 EPS for the current fiscal year.

Insider Activity at Prestige Consumer Healthcare

In related news, SVP Mary Beth Fritz sold 1,678 shares of the firm’s stock in a transaction dated Monday, March 10th. The stock was sold at an average price of $90.00, for a total transaction of $151,020.00. Following the transaction, the senior vice president now directly owns 17,157 shares of the company’s stock, valued at approximately $1,544,130. This trade represents a 8.91 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. 1.60% of the stock is currently owned by insiders.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.